Dense Gas Processing of Micron-Sized Drug Formulations Incorporating Hydroxypropylated and Methylated Beta-Cyclodextrin
- First Online:
- 115 Downloads
Because of their importance in pharmaceutical applications, hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin have been selected to study the formation of micronized complexes incorporating active pharmaceutical ingredients (APIs) and cyclodextrins (CDs) by dense gas (DG) processing.
A single-step DG technique was used as an alternative to conventional methods for the manufacturing of API/CD complexes. The DG technology is highly attractive in the pharmaceutical industry because of its potential to generate micronized particles with controlled particle size distributions at moderate operating conditions. The effect of the aerosol solvent extraction system (ASES) processing on the dissolution performance of naproxen (NPX) was examined.
The CDs were produced as microspheres smaller than 3 μm. The coprecipitation of each CD with NPX resulted in the production of microparticles with enhanced dissolution rates.
The ASES was operated under mild conditions and generated micron-sized spherical particles that could be of particular interest in formulations for pulmonary delivery.
Particular advantages of the technique are that (1) nontoxic solvents are used, and (2) it is suitable for the processing of thermally labile compounds. The proposed process can create opportunities to improve current administration routes and exploit novel delivery systems for drug formulations incorporating CDs.
Key Wordscarbon dioxide cyclodextrin dense gases pulmonary drug delivery supercritical fluids
active pharmaceutical ingredient
aerosol solvent extraction system
depressurization of an expanded liquid organic solution
particles from gas-saturated solutions
supercritical assisted atomization
- 1.Szejtli, J. 1988Cyclodextrin TechnologyKluwer Academic PublishersDordrecht, The NetherlandsGoogle Scholar
- 3.Thompson, D. O. 1997Cyclodextrins-enabling excipients: their present and future use in pharmaceuticalsCrit. Rev. Ther. Drug Carr. Syst.141104Google Scholar
- 7.Szejtli, J., Osa, T. 1996CyclodextrinsElsevier Science Ltd.New YorkGoogle Scholar
- 8.Rajewski, R. A., Stella, V. J. 1996Pharmaceutical applications of cyclodextrins. 2. In vivo drug deliveryJ. Pharmacol. Sci.8511431169Google Scholar
- 10.Pinto, J. M. C. L., Marques, H. M. C. 1999Beclomethasone/cyclodextrin inclusion complex for dry powder inhalationSTP Pharma Sci.9253256Google Scholar
- 11.A. Clark, M. C. Kuo, and C. Lalor. Phospholipids, cyclodextrins, starch, and cellulose as hygroscopic growth inhibitors in dry powders for pulmonary drug delivery, Inhale Therapeutic Systems, Inc., USA, WO, 2000, pp. 46.Google Scholar
- 13.Y. H. Chou and D. L. Tomasko. Gas crystallization of polymer–pharmaceutical composite particles. The 4th International Symposium on Supercritical Fluids, Vol. A, ISSF, Sendai, Japan, 1997, pp. 55–57.Google Scholar
- 14.Bettinetti, G., Gazzaniga, A., Mura, P., Giordano, F., Setti, M. 1992Thermal behavior and dissolution properties of naproxen in combinations with chemically modified β-cyclodextrinsDrug Dev. Ind. Pharm.183953Google Scholar
- 16.Charoenchaitrackool, M., Dehgani, F., Foster, N. R. 2002Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrinInt. J. Pharm.239103112Google Scholar
- 17.Thiering, R., Dehghani, F., Dillow, A., Foster, N. R. 2000Solvent effects on the controlled dense gas precipitation of model proteinsJ. Chem. Technol. Biotechnol.754253Google Scholar
- 18.Thiering, R., Dehghani, F., Dillow, A., Foster, N. R. 2000The influence of operating conditions on the dense gas precipitation of model proteinsJ. Chem. Technol. Biotechnol.752941Google Scholar
- 19.G. S. Gurdial. Solubility behaviour of organic compounds in supercritical carbon dioxide, PhD dissertation, School of Chemical Engineering and Industrial Chemistry, University of New South Wales, Sydney, Australia, 1991.Google Scholar
- 23.Reverchon, E., Porta, G. 2003Micronization of antibiotics by supercritical assisted atomizationJ. Supercrit. Fluids26243252Google Scholar
- 24.Fages, J., Lochard, H., Letourneau, J.-J., Sauceau, M., Rodier, E. 2004Particle generation for pharmaceutical applications using supercritical fluid technologyPowder Technol.141219226Google Scholar
- 25.X. Han, A. R. Baxter, K. W. Koelling, D. L. Tomasko, and L. J. Lee. Influences of solubility and viscosity in the polystyrene/CO2 microcellular foaming extrusion, 60th Annual Technical Conference—Society of Plastics Engineers, San Francisco, CA, 2002, pp. 1910–1914.Google Scholar
- 26.A. J. Busby, K. S. Morley, C. J. Roberts, M. S. Watson, P. B. Webb, B. Wong, J. Zhang, G. Kokturk, and S. M. Howdle. Polymers, biomaterials and supercritical fluids, Proceedings of the 8th Meeting on Supercritical Fluids, Vol. 1, Bordeaux, 2002, pp. 115–120.Google Scholar
- 27.Trotta, F., Zanetti, M., Camino, G. 2000Thermal degradation of cyclodextrinsPolym. Degrad. Stab.69373379Google Scholar
- 28.J. Sztatisz, S. Gal, J. Komives, A. Stadler-Szoke, and J. Szejtli. Thermoanalytical investigations on cyclodextrin inclusion compounds, 1st International Symposium on Cyclodextrins, Budapest, 1981.Google Scholar